Progen
Making life science better. Together.
Our commitment to scientists is to support them in making new scientific discoveries and groundbreaking research within the life sciences and gene therapy. It is our underlying mission, to help progress new therapies safely, quickly and affordably, so together we can provide solutions to people suffering from poor health and affected by disease every day.
PROGEN is made up of a team of experts within AAV and the life sciences and is partnered with gene therapy experts worldwide. We are more than just a manufacturer of antibodies, proteins and ELISAs kits. We strive to understand what scientists need, so we can create solutions and ultimately deliver high quality antibody and exclusive AAV products, which solve your research challenges within academia, biotech and pharma, and ensure PROGEN can continue to be a trusted and reliable partner.
Featured Products
- AAV1 Titration ELISA – Unique microtiter plate enzyme immunoassay for the quantitation of virions and assembled empty capsids of AAV1. The capture-antibody detects a conformational epitope not present on unassembled capsid proteins.
- OptiPrep™ – Iodixanol – OptiPrep™ is a ready made, sterile and endotoxin tested solution of Iodixanol, 5,5’-[(2-hydroxy-1-3 propanediyl)-bis(acetylamino)] bis [N,N’- bis(2,3 dihydroxypropyl- 2,4,6-triiodo-1, 3-benzenecarboxamide], designed for the in vitro isolation of biological particles.
- anti-Alkaline Phosphatase (intestinal) mouse monoclonal, V17.1, purified – V17.1 react with intestinal alkaline phosphatase, an enzyme widely used in immunodetection tests. Positive Control: Intestinal alkaline phosphatase
- anti-AAV1, human chimeric, ADK1a-h1 – Our human chimeric AAV antibodies are derived from our mouse monoclonal AAV antibodies and are a combination of the mouse antigen binding region and a human Fc region. Therefore, it provides the well-known characteristics of the corresponding mouse monoclonal antibody (anti-AAV1, ADK1a, Cat. No. 610150) like binding affinity, cross-reactivity and neutralization activity combined with a human Fc region allowing the use in an anti-human secondary antibody detection system. Many humans in the general population have developed antibodies against AAV as a result of naturally acquired infections, which might affect efficacy and safety of the gene transfer using AAV vectors. Therefore, testing for pre-existing AAV antibodies in patient sera is an indispensable step for the selection of patients for AAV gene therapy clinical trials. Our human chimeric AAV antibodies are close to the human derived samples, making them the ideal positive control for reproducible and comparable serological assays.
Product Categories
Contact Us
The Krishgen support team strives to provide swift responses and resolution to your queries.